Description
Product Usage Information
CBR-5884 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 0.99 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 2 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
CBR-5884 is a small-molecule inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first step in the serine biosynthesis pathway. An increase in serine biosynthesis supports growth and proliferation of cancer cells, which is seen by amplification and overexpression of PHGDH in some melanoma and breast cancers (1). CBR-5884 inhibited the proliferation of melanoma and breast cancers that displayed increased levels of serine synthesis, but had no effect on cells that rely on extracellular serine uptake. CBR-5884 disrupted PHGDH oligomerization and decreased serine biosynthesis by 30% in cancer cells (2). CBR-5884 treatment of teratocarcinoma cells significantly decreased the growth rate in a dose-dependent manner (3). Inhibition of PHGDH and serine biosynthesis caused accumulation of reactive oxygen species, DNA damage, and apoptosis in leukemic cells (4). Treating human myeloma cells with CBR-5884 reduced proliferation, while inhibition of PHGDH by CBR-5884 reduced proliferation and sensitized glioblastoma cells to hypoxia-induced cell death (5,6).
Alternate Names
Ethyl 5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-carboxylate
